ClinicalTrials.gg
RecruitingNCT05539040RGanglia-AFUpdated Sep 28, 2023

The Role of Right Atrial Ectopy Triggering Ganglionated Plexuses in AF

An interventional study of Right Atrial ganglionated plexus ablation and Holter Monitor in Cardiac Arrhythmia and Atrial Fibrillation, sponsored by Imperial College London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-09-28.

Primary conditionAtrial FibrillationRegistry: Arrhythmias, CardiacReclassifiedWhy we changed it
Registry
Arrhythmias, Cardiac — the first condition term the registry derived for this study.
ClinicalTrials.gg
Atrial Fibrillation
Why
  1. The study's listed conditions name Atrial Fibrillation, a narrower term within Arrhythmias, Cardiac.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Imperial College London · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Atrial Fibrillation by Imperial College London — 2 open to participants now, 5 under way, none of them phase 3. Atrial Fibrillation · Imperial College London.

Started
2023
with 1 other
No phase
7 of 12
2 open now
Registered
10th of 12
by date

Among the 12 studies in Atrial Fibrillation by Imperial College London, this one is one of 2 that started in 2023, is one of 7 with no phase, and was the 10th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

2 of the 12 studies in Atrial Fibrillation by Imperial College London are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Atrial Fibrillation by Imperial College London, or all of them as a file.
02

Study summary

Atrial fibrillation (AF) is the most common rhythm disturbance of the heart. It can affect people of any age but usually happens as we get older. It can cause palpitations, breathlessness, lethargy, and fainting attacks. It is also associated with an increased risk of strokes.

The best treatment for it at the moment involves burning or freezing (ablation) the heart muscle in a part of the heart called the left atrium. The ablation injures the heart muscle around the so-called pulmonary veins and the procedure is called a 'pulmonary vein isolation'. This procedure work in about 60% of people.

The study team have found that there are nerve endings in the heart that also cause AF and have shown that ablating these nerve endings also prevents AF. These Nerve endings are known as ganglionated plexuses (GPs).

The study team would now like to perform a trial in people who still have AF after the usual pulmonary vein procedure. The study team hope that ablating the nerve endings that cause AF (GPs), we will stop their AF coming back. The study team will compare this procedure to the normal approach of doing the pulmonary vein isolation again

Read the detailed description

Atrial fibrillation (AF) is the most common heart rhythm disturbance and causes physical discomfort and strokes.

The the best long-term treatment of AF is catheter ablation in a part of the heart called the left atrium and works in about 60-70% of patients.

The study team have discovered that that there are nerve endings in the heart that cause AF (GP sites). The study team have previously treated patients with AF by ablating these nerve endings (GP ablation) in a part of the heart called the left atrium.

The study team have treated patients with AF by ablation of these nerve ending in the left atrium. The treatment worked in a similar number of people to the standard treatment but caused less heart injury than the standard treatment

There are similar nerve endings in another part of the heart called the right atrium. The study team want to find out if ablating these nerve endings in the right atrium can help people for whom the standard treatment in the left atrium has not worked.

STUDY PROTOCOL: The study will run at at one hospital (Hammersmith Hospital). The study team will look at the information on patients who have been placed on the waiting list for an AF ablation. The study team will approach patients who have previously had an ablation and coming back for another procedure.

Patients will be given information about the study and discuss the issues with the research team. Patients who decide to participate will be allocated an anonymised number and their information included on a research database and will be encrypted for use only by the research team.

Patients in the study will be randomly assigned to one of two treatment pathways. All patients will then continue with their standard NHS treatment to prepare them for the procedure. All patients will have all the steps of the ablation done in the same way, including the repeat pulmonary vein isolation procedure which they have been advised to have by their own doctor.

The group of patients allocated to receive right sided ablation to treat the nerve endings procedure will have this done in addition to the repeat pulmonary vein isolation.

The study team will aim to recruit 116 patients to the study. All patients will stop any heart rhythm medication prior to the procedure. A 48 hour heart rhythm monitor will be obtained prior to patients' procedure. The study team will also ask patients to complete a survey to assess their quality of life.

All patients will have their procedures under general anaesthesia. An ultrasound from inside the oesophagus will be used to exclude blood clot in the heart. Access to the heart will be through the veins in the leg and transeptal puncture to get into the left atrium. All patients will first undergo a repeat pulmonary vein isolation. 3D mapping software will be used to identify the pulmonary veins and then these will be isolated from the rest of the heart by using radiofrequency energy to burn the tissue which connects these areas to the rest of the heart. This will be the end of the procedure for those patients receiving standard treatment.

The patients allocated to right atrial GP ablation will then have map of the right atrium created and the sites which contains the nerves supplying the heart identified. These will be found using high-frequency electrical stimulation delivered by a custom-built stimulator that has been shown to be comparable to the existing technology. When the sites of these nerves are found, they will be marked on the map of the right atrium and then they will undergo ablation with radiofrequency energy till they are no longer detectable.

If the patient is not in a normal rhythm before or during the procedure, then they may require an electric shock to return them to normal. The procedures in each arm will take between 2hrs and 3hrs to perform

Follow Up:

All heart rhythm medication patient used to take before ablation will be continued during the 3 months after procedure, except for amiodarone. After 3 months, patients will stop all heart rhythm medication if they are well and free of symptoms or AF.

At 3, 6, 9, 12 months following patients' procedures, 48hour heart monitors will be fitted or implanted devices will be reviewed, to assess if any atrial fibrillation has happened. The Quality of life survey will be repeated at 6 and 12 months after the ablation.

03

Conditions studied

  • Cardiac Arrhythmia
  • Atrial Fibrillation

Browse trials for

Keywords

  • Atrial Fibrillation
  • Ganglionated plexus
  • Arrhythmia
  • Cardiology
  • Right atrium
  • Ectopy
  • Electrophysiology
  • GP
  • AF
04

In context

Atrial Fibrillation Reclassified

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

This study's planned enrollment of 116 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

Imperial College London is the lead sponsor of 844 studies on the registry; 181 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Compared within Atrial Fibrillation, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Arrhythmias, Cardiac. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females from 18 to 85yrs old
  • Symptomatic paroxysmal atrial fibrillation
  • Suitable candidate for catheter ablation
  • Signed

Exclusion criteria

Exclusion Criteria:

  • to catheter ablation
  • Contraindication for general anaesthetic
  • Presence of a left ventricular thrombus
  • Valvular disease that is grade moderate or greater
  • Any form of cardiomyopathy
  • Severe cerebrovascular disease
  • Active gastrointestinal bleeding
  • Serum Creatinine >200umol/L/ on dialysis/ at risk of dialysis
  • Active infection or fever
  • shorter than the duration of the trial
  • Allergy to contrast
  • Moderate to severe heart failure and/or Class III-IV
  • Bleeding or clotting disorders or inability to receive heparin
  • Uncontrolled diabetes ( ≥73mmol/mol or HbA1c ≤64mmol/mol and Fasting Blood Glucose ≥9.2mmol/L)
  • needing therapy
  • Pregnancy or women of not using a highly effective method of
  • Unable to give
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    Intervention

    Right atrial GP ablation in addition to pulmonary vein isolation

    Procedure: Right Atrial ganglionated plexus ablation · Diagnostic Test: Holter Monitor · Procedure: Pulmonary vein isolation · Diagnostic Test: Personal ECG recordings · Other: Quality of life questionnaire

  • Active comparator
    Control

    PVI alone with no GP mapping or ablation

    Diagnostic Test: Holter Monitor · Procedure: Pulmonary vein isolation · Procedure: Right cavo-tricuspid and left roof linear ablation · Diagnostic Test: Personal ECG recordings · Other: Quality of life questionnaire

Interventions

  • ProcedureRight Atrial ganglionated plexus ablation

    A 3D electroanatomic map of the right atrium will be made. During sinus rhythm, the ablation catheter will be positioned at a spot to test with HFS. The right atrium will be paced at a fixed rate, for up to four beats to ensure that there is no ventricular capture then a short burst of HFS will be synchronized to each paced stimulus for up to 15 trains. This will be performed using a custom-built GP stimulator that has been validated for reproducibility against Grass Stimulator (AstroMed). All Sites will be marked on the 3D map and the positive sites will be ablated at the end of the mapping. If the patient converts to AF, then DC cardioversion will be performed. If mapping in sinus rhythm is not feasible, HFS will be performed continuously for several seconds to identify atrioventricular dissociating GPs (AVD-GPs). Every ablated GP site will be re-tested with HFS at the end of the procedure until they are all rendered non-functional.

  • Diagnostic testHolter Monitor

    48 hour Holter monitors will be performed post procedure to monitor for recurrence of AF. These will be performed at 3, 6, 9, 12 months

  • ProcedurePulmonary vein isolation

    Transseptal puncture for access into the left atrium will be guided by TOE and fluoroscopy. ACT will be maintained at 300s with heparin. A 3D electroanatomic map of the left atrium will be created and all PVs will be identified. Touch-up radiofrequency ablation will be performed at electrical gaps around the reconnected PVs until complete PVI is achieved.

  • ProcedureRight cavo-tricuspid and left roof linear ablation

    CONTROL ARM (Redo-PVI) only: If all Pulmonary veins are isolated at the start of the procedure, the operator will be allowed to perform a right cavo-tricuspid and left roof linear ablation.

  • Diagnostic testPersonal ECG recordings

    All patients will be provided with an AliveCor KardiaMobile-6L ECG recorder. The device will continue to be used within its CE-marked and NICE-approved purpose. Patients will be asked to take a daily recording from this, once the blanking period is over, in addition to taking a recording if symptomatic. Patients will submit this to the connected care team at Hammersmith Hospital via a secure NHS.net email address, who will assess the recordings both for the study and clinical purposes.

  • OtherQuality of life questionnaire

    A Quality of life questionnaire will be performed at baseline, 6 and 12 months to assess the effect of the procedures on patients quality of life.

07

What researchers measure

Primary outcomes

  1. atrial arrhythmia lasting >30secs

    Any recorded atrial arrhythmia lasting \>30seconds will meet the primary endpoint for the trial.

    Time frame: 1 year

Secondary outcomes

  1. Complications

    Number of patients experiencing a procedural complication.

    Time frame: 1 year

  2. Usage of antiarrhythmic drugs

    number of patients using antiarrhythmic drugs to control symptoms and pathology of AF

    Time frame: 1 year

  3. Quality of life questionnaire

    Quality of life will be assess pre and post procedure to assess if any improvement has been seen post procedure. An increase in the AFEQT questionnaire score will reflect a decrease in quality of life

    Time frame: 1 year

  4. Re-do procedures

    number of repeat procedures will be assessed and compared between the to arms

    Time frame: 1 year

  5. Radiofrequency time

    The quantity of radiofrequency ablation in each arm of the trail will be assessed.

    Time frame: day of the procedure.

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No — There are no plans to share individual participant data with other researchers

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Feb 2026, 36 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 36 months is close to that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2022
First posted
Sep 14, 2022
StartActual
Feb 21, 2023
Primary completionEst.
Feb 21, 2026
CompletionEst.
Dec 2, 2027
Last update
Sep 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05539040
Responsible party
Sponsor
First posted
Sep 14, 2022
Start date
Feb 21, 2023
Primary completion
Feb 21, 2026 (estimated)
Completion
Dec 2, 2027 (estimated)
Last update
Sep 28, 2023

Study contacts

Jamie Kay, MBBS BMedSci
Contact
jamie.kay@imperial.ac.uk
02033131000 ext. via switch
Prapa Kanagaratnam, MBBChir, PhD
principal investigator · Imperial College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion